The estimated Net Worth of Michel Dahan is at least $3.13 Million dollars as of 13 May 2024. Mr. Dahan owns over 34,840 units of Akebia Therapeutics stock worth over $967,812 and over the last 9 years he sold AKBA stock worth over $675,727. In addition, he makes $1,485,250 as Chief Operating Officer and Senior Vice President at Akebia Therapeutics.
Michel has made over 20 trades of the Akebia Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 34,840 units of AKBA stock worth $43,898 on 13 May 2024.
The largest trade he's ever made was selling 95,478 units of Akebia Therapeutics stock on 24 May 2023 worth over $116,483. On average, Michel trades about 8,783 units every 106 days since 2016. As of 13 May 2024 he still owns at least 672,092 units of Akebia Therapeutics stock.
You can see the complete history of Mr. Dahan stock trades at the bottom of the page.
Michel Dahan serves as Chief Operating Officer, Senior Vice President of the Company. Previously, Mr. Dahan was Akebia’s Senior Vice President, Chief Business Officer from December 2013 to January 2020. Prior to joining Akebia, from 2010 to 2013, Mr. Dahan held various positions at Inspiration Biopharmaceuticals, Inc., a company that filed for protection under Chapter 11 of the U.S. Bankruptcy Code in October 2012 prior to the successful sale of its hemophilia assets to Cangene Corporation and Baxter International in early 2013 for total aggregate consideration that could exceed $1 billion, most recently as Vice President, Commercial Development and Strategic Planning, and led global marketing and commercial development in preparation for two global launches. Prior to that, from 2003 to 2010, Mr. Dahan served in various roles for Ipsen, most recently as International Product Director, working on global marketing and strategic planning for their hemophilia franchise, and Strategic Planning Director. Previously, he was in Global Business Development and Licensing for Ipsen. He began his career at BNP Paribas in the investment banking division in 2002. He earned his graduate degree in business administration at HEC Paris (France), his maitrise in mathematics from University Paris VI (France), and he completed an executive education program (PLD) at Harvard Business School.
As the Chief Operating Officer and Senior Vice President of Akebia Therapeutics, the total compensation of Michel Dahan at Akebia Therapeutics is $1,485,250. There are 1 executives at Akebia Therapeutics getting paid more, with John Butler having the highest compensation of $4,316,960.
Michel Dahan is 41, he's been the Chief Operating Officer and Senior Vice President of Akebia Therapeutics since 2020. There are 19 older and no younger executives at Akebia Therapeutics. The oldest executive at Akebia Therapeutics Inc. is Adrian Adams, 69, who is the Independent Chairman of the Board.
Michel's mailing address filed with the SEC is C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE, MA, 02142.
Over the last 11 years, insiders at Akebia Therapeutics have traded over $3,056,393 worth of Akebia Therapeutics stock and bought 2,141,907 units worth $27,915,834 . The most active insiders traders include Holdings A/S Novo, Muneer A Satter, and Mark J Enyedy. On average, Akebia Therapeutics executives and independent directors trade stock every 28 days with the average trade being worth of $43,534. The most recent stock trade was executed by Nicole R. Hadas on 13 May 2024, trading 12,016 units of AKBA stock currently worth $15,140.
akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.
Akebia Therapeutics executives and other stock owners filed with the SEC include: